What is the treatment for Herpes Simplex Virus (HSV) throat infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The treatment for Herpes Simplex Virus (HSV) throat infection typically involves antiviral medications such as acyclovir, valacyclovir, or famciclovir. For an acute HSV throat infection (herpetic pharyngitis), oral acyclovir 400mg five times daily for 5-10 days is commonly prescribed, as seen in various guidelines 1. Alternatively, valacyclovir 1000mg twice daily or famciclovir 250mg three times daily for the same duration may be used. These medications work by inhibiting viral DNA replication, which helps reduce the severity and duration of symptoms. Supportive care is also important and includes:

  • Adequate hydration
  • Pain management with over-the-counter analgesics like acetaminophen or ibuprofen
  • Salt water gargles to soothe the throat. For severe cases or in immunocompromised patients, intravenous acyclovir 5-10mg/kg every 8 hours may be necessary, as suggested by the guidelines 1. It's essential to start antiviral therapy as early as possible after symptom onset for maximum effectiveness. For patients with frequent recurrences, suppressive therapy with lower daily doses of antivirals may be considered to prevent future outbreaks, as recommended by the guidelines 1.

From the FDA Drug Label

Herpes Simplex Infections in Immunocompromised Patients Acyclovir for Injection is indicated for the treatment of initial and recurrent mucosal and cutaneous herpes simplex (HSV-1 and HSV-2) in immunocompromised patients The treatment for Herpes Simplex Virus (HSV) throat infection is Acyclovir (IV), the dosage is 5 to 15 mg/kg every 8 hours 2.

  • Key points:
    • Acyclovir is indicated for the treatment of initial and recurrent mucosal and cutaneous herpes simplex (HSV-1 and HSV-2) in immunocompromised patients 2
    • The dosage of acyclovir is dependent on the patient's renal function, with adjustments made based on creatinine clearance 2

From the Research

Treatment Options for HSV Throat Infection

  • The primary treatment for Herpes Simplex Virus (HSV) throat infection involves the use of antiviral medications, with acyclovir and its derivatives being the gold standard for prevention and treatment 3.
  • In cases where acyclovir resistance develops, alternative treatments such as cidofovir and foscarnet may be used 3.
  • Other antiviral agents like famciclovir and valacyclovir have also been shown to be effective in treating HSV infections, with valacyclovir being more effective than famciclovir in suppressing genital herpes and associated shedding 4, 5.
  • Valacyclovir has been approved for the treatment of herpes labialis, genital herpes, and herpes zoster, and has been shown to be safe and effective in these indications 6.
  • Novel antiviral approaches, including therapeutic vaccines and small molecule inhibitors, are being developed for the treatment of HSV infections, with some showing promising results in clinical trials 7.

Antiviral Medications

  • Acyclovir: gold standard for prevention and treatment of HSV infections 3.
  • Valacyclovir: effective in treating herpes labialis, genital herpes, and herpes zoster, and has been shown to be safe and effective in these indications 6.
  • Famciclovir: effective in treating HSV infections, but may not be as effective as valacyclovir in suppressing genital herpes and associated shedding 4, 5.
  • Cidofovir and foscarnet: alternative treatments for acyclovir-resistant HSV infections 3.

Future Treatment Options

  • Therapeutic vaccines: have shown promise in clinical trials and may provide a new treatment option for HSV infections 7.
  • Small molecule inhibitors: such as amenamevir and pritelivir, have shown promising results in clinical trials and may provide a new treatment option for HSV infections 7.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.